GlycoFi Inc., A Wholly-Owned Subsidiary of Merck & Co. Inc., 21 Lafayette Street, Suite 200, Lebanon, NH 03766, USA.
Glycobiology. 2011 Dec;21(12):1606-15. doi: 10.1093/glycob/cwr082. Epub 2011 Jul 27.
The N-glycosylation pathway in Pichia pastoris has been humanized by the deletion of genes responsible for fungal-type glycosylation (high mannose) as well as the introduction of heterologous genes capable of forming human-like N-glycosylation. This results in a yeast host that is capable of expressing therapeutic glycoproteins. A thorough investigation was performed to examine whether glycoproteins expressed in glycoengineered P. pastoris strains may contain residual fungal-type high-mannose structures. In a pool of N-linked glycans enzymatically released by protein N-glycosidase from a reporter glycoprotein expressed in a developmental glycoengineered P. pastoris strain, an oligosaccharide with a mass consistent with a Hexose(9)GlcNAc(2) oligosaccharide was identified. When this structure was analyzed by a normal-phase high-performance liquid chromatography (HPLC), its retention time was identical to a Man(9)GlcNAc(2) standard. However, this Hexose(9)GlcNAc(2) oligosaccharide was found to be resistant to α-1,2-mannosidase as well as endomannosidase, which preferentially catabolizes endoplasmic reticulum oligosaccharides containing terminal α-linked glucose. To further characterize this oligosaccharide, we purified the Hexose(9)GlcNAc(2) oligosaccharide by HPLC and analyzed the structure by high-field one-dimensional (1D) and two-dimensional (2D) (1)H NMR (nuclear magnetic resonance) spectroscopy followed by structural elucidation by homonuclear and heteronuclear 1D and 2D (1)H and (13)C NMR spectroscopy. The results of these experiments lead to the identification of an oligosaccharide α-Man-(1 → 2)-β-Man-(1 → 2)-β-Man-(1 → 2)-α-Man-(1 → 2) moiety as part of a tri-antennary structure. The difference in enzymatic reactivity can be attributed to multiple β-linkages on the α-1,3 arm of the Man(9)GlcNAc(2) oligosaccharide.
毕赤酵母中的 N-糖基化途径已通过删除负责真菌型糖基化(高甘露糖)的基因以及引入能够形成类似人源的 N-糖基化的异源基因进行了人源化。这导致酵母宿主能够表达治疗性糖蛋白。进行了彻底的研究,以检查在糖基工程化毕赤酵母菌株中表达的糖蛋白是否可能含有残留的真菌型高甘露糖结构。在由在发育性糖基工程化毕赤酵母菌株中表达的报告糖蛋白的蛋白 N-糖苷酶酶促释放的 N-连接聚糖池中,鉴定出一种质量与 Hexose(9)GlcNAc(2)寡糖一致的寡糖。当通过正相高效液相色谱 (HPLC) 分析该结构时,其保留时间与 Man(9)GlcNAc(2)标准品相同。然而,发现这种 Hexose(9)GlcNAc(2)寡糖对 α-1,2-甘露糖苷酶以及内甘露糖苷酶具有抗性,内甘露糖苷酶优先分解含有末端α-连接葡萄糖的内质网寡糖。为了进一步表征这种寡糖,我们通过 HPLC 对 Hexose(9)GlcNAc(2)寡糖进行了纯化,并通过高场一维 (1D) 和二维 (2D) (1)H NMR(核磁共振)光谱对其结构进行了分析,然后通过同核和异核 1D 和 2D (1)H 和 (13)C NMR 光谱对结构进行了阐明。这些实验的结果导致鉴定出一种寡糖α-Man-(1 → 2)-β-Man-(1 → 2)-β-Man-(1 → 2)-α-Man-(1 → 2)部分作为三触角结构的一部分。酶反应性的差异可归因于 Man(9)GlcNAc(2)寡糖的α-1,3 臂上的多个β键。